"""
Question: 1101 

Evidence: Here, we performed a retrospective analysis to obtain a molecular characterisation of the infection among patients who were diagnosed in 2008–2014 and related the findings to demographic and clinical parameters. A total of 17 transmission clusters were identified, including 44/186 (23.7%) participants.

Rationale: The paper describes an original retrospective analysis of a cohort diagnosed in 2008–2014 and presents new results (e.g., number of clusters, proportions), indicating the data and findings were not previously published.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Pol sequences were obtained by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The methods explicitly state that HIV-1 pol sequences were generated, confirming that the paper reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Pol sequences were obtained by Sanger sequencing. Transmission clusters were identified by phylogenetic analysis (maximum likelihood method, confirmed by Bayesian analysis).

Rationale: The study focused on clinical sequencing and phylogenetic analyses; there is no mention of laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list. Transmission clusters were identified by phylogenetic analysis (maximum likelihood method, confirmed by Bayesian analysis).

Rationale: The paper reports genotypic resistance evaluation and phylogenetics but does not describe any phenotypic antiretroviral susceptibility testing.

Answer: No
"""

"""
Question: 2101 

Evidence: Pol sequences were obtained by Sanger sequencing. To determine HIV-1 subtype, pol sequences were aligned with full-length reference sequences retrieved from the LANL database.

Rationale: Although sequences were generated and analyzed, the paper does not report any GenBank (or other database) accession numbers for the study sequences.

Answer: No
"""

"""
Question: 2102 

Evidence: Pol sequences were obtained by Sanger sequencing. To determine HIV-1 subtype, pol sequences were aligned with full-length reference sequences retrieved from the LANL database.

Rationale: The paper does not provide GenBank accession numbers for any of the clinical sequences; therefore, it also does not provide accession numbers for non-laboratory isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: Pol sequences were obtained by Sanger sequencing. To determine HIV-1 subtype, pol sequences were aligned with full-length reference sequences retrieved from the LANL database.

Rationale: No accession numbers are reported anywhere in the text, so none can be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with the additional RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I. TDR was present in 16/186 (8.6%) participants.

Rationale: The paper reports overall TDR prevalence and which mutation list was used for evaluation, but it does not provide per-individual mutation lists.

Answer: No
"""

"""
Question: 2301 

Evidence: Individuals in the acute and recent phases of the infection play an important role in sustaining HIV transmission. We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The study explicitly concerns HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Molecular subtyping showed that clade B accounted for 67.7% sequences. The most common non-B clades were CRF02_AG (21/186, 11.3%), F1 (17/186, 9.1%) and C (7/186, 3.8%). Other non-B clades were CRF18_cpx, CRF01_AE, G, A1, CRF12_BF, CRF19_cpx and CRF28_BF.

Rationale: The results list all subtypes and CRFs identified among the sequenced viruses.

Answer: B, CRF02_AG, F1, C, CRF18_cpx, CRF01_AE, G, A1, CRF12_BF, CRF19_cpx, CRF28_BF
"""

"""
Question: 2303 

Evidence: Pol sequences (containing the full-length protease and the first 330–335 reverse transcriptase (RT) codons), obtained for routine baseline drug resistance testing, were performed at each centre by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The methods specify that the sequenced region was pol, specifically protease and the first 330–335 codons of reverse transcriptase.

Answer: pol (protease and the first 330–335 codons of reverse transcriptase)
"""

"""
Question: 2304 

Evidence: Pol sequences were obtained by Sanger sequencing. Molecular subtyping showed that clade B accounted for 67.7% sequences.

Rationale: The paper explicitly reports results from pol sequencing, including subtype distributions and clustering.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Among 186 individuals with PHI, 153 (82.3%) were from cities in the north of Italy (Milan: 54, Brescia: 38, Monza: 20, Bergamo: 16, Modena: 22, Genoa: 3); 26 (14.0%) from Rome; and 7 (3.8%) from Sardinia (Sassari 2) and Sicily (Catania 5). ... across Italy.

Rationale: The sequences are from individuals presenting at centers across Italy, with detailed city distribution.

Answer: Italy (including Milan, Brescia, Monza, Bergamo, Modena, Genoa, Rome, Sardinia [Sassari], and Sicily [Catania])
"""

"""
Question: 2402 

Evidence: ... individuals who in 2008–2014 presented with primary HIV-1 infection (PHI) at 11 urban centres across Italy. ... who were diagnosed in 2008–2014.

Rationale: The paper states the time frame of diagnoses/sampling as 2008–2014.

Answer: 2008–2014
"""

"""
Question: 2502 

Evidence: Pol sequences were obtained by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The sequencing method is explicitly Sanger.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Pol sequences were obtained by Sanger sequencing. 

Rationale: Only Sanger sequencing is described; no NGS methods are mentioned.

Answer: No
"""

"""
Question: 2504 

Evidence: Pol sequences were obtained by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The paper describes bulk Sanger genotyping from plasma with no mention of cloning steps prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Pol sequences were obtained by Sanger sequencing. 

Rationale: Single-genome sequencing is not mentioned; instead, standard population Sanger sequencing was used.

Answer: No
"""

"""
Question: 2506 

Evidence: Pol sequences were obtained by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: There is no description of molecular cloning; the approach is direct population sequencing.

Answer: No
"""

"""
Question: 2601 

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples. Pol sequences were obtained by Sanger sequencing.

Rationale: The sequencing was done on plasma-derived HIV RNA.

Answer: Yes
"""

"""
Question: 2602 

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The study did not perform PBMC sequencing; only plasma samples were used.

Answer: No
"""

"""
Question: 2603 

Evidence: A phylogenetic tree was constructed encompassing all 186 sequences. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: All 186 sequences were from plasma samples; thus, 186 plasma virus sequences were reported.

Answer: 186
"""

"""
Question: 2604 

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: Since sequencing was exclusively from plasma, PBMC virus sequencing count is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI), defined as detectable plasma HIV-1 RNA plus either: (1) a negative third or fourth generation HIV immunoassay or (2) an indeterminate or positive western blot or RIBA, without reactivity of p31 band. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: Inclusion required detectable plasma HIV-1 RNA, indicating active replication at sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: All HIV-1 pol genotype analyses were performed on plasma samples. 

Rationale: Sequencing was done on plasma RNA, not on proviral DNA from cellular reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: The PHI cohort comprised 186 participants (159/186, 85.5% males) with median age 44 years. 

Rationale: The study population are adults; there is no mention of infants/children.

Answer: No
"""

"""
Question: 2702 

Evidence: Italian Network of Acute HIV Infection is a nationwide,multicentre cohort study... Here, we performed a retrospective analysis... The study was approved by the Ethics Committee... It was conducted according to the declaration of Helsinki principles.

Rationale: This is an observational cohort study; there is no indication that participants were enrolled in a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: Italian Network of Acute HIV Infection is a nationwide,multicentre cohort study... Here, we performed a retrospective analysis...

Rationale: Since it is not a clinical trial, it cannot be that all individuals were in a trial.

Answer: No
"""

"""
Question: 3101 

Evidence: A phylogenetic tree was constructed encompassing all 186 sequences. 

Rationale: The total number of individuals with sequences is 186.

Answer: 186
"""

"""
Question: 3102 

Evidence: A phylogenetic tree was constructed encompassing all 186 sequences. Pol sequences were obtained by Sanger sequencing.

Rationale: All individuals in the cohort contributed sequences, as evidenced by the tree including all 186 sequences.

Answer: Yes
"""

"""
Question: 4101 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). Pol sequences were obtained by Sanger sequencing.

Rationale: Sequences were obtained from ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: The cohort was treatment-naïve at baseline; no sequences from previously treated individuals are reported.

Answer: No
"""

"""
Question: 4103 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). 

Rationale: Only ART-naive individuals were sequenced; there were no ART-experienced sequences.

Answer: No
"""

"""
Question: 4104 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). A phylogenetic tree was constructed encompassing all 186 sequences.

Rationale: All sequences were from ART-naive individuals, totaling 186.

Answer: 186
"""

"""
Question: 4105 

Evidence: ART initiation§ — <3 months from diagnosis: 43 (24.7); ≥3 months from diagnosis: 131 (75.3); §Data available for 174/186 individuals. We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI).

Rationale: ART initiation timing data were missing for some participants, and detailed ART histories/regimens are not provided; thus, complete ART history is not available for all.

Answer: No
"""

"""
Question: 4201 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... TDR was present in 16/186 (8.6%) participants.

Rationale: The paper reports the prevalence of transmitted resistance.

Answer: Yes
"""

"""
Question: 4202 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... TDR was present in 16/186 (8.6%) participants.

Rationale: In a treatment-naïve cohort, TDR represents pretreatment resistance; thus, pretreatment resistance prevalence is reported.

Answer: Yes
"""

"""
Question: 4301 

Evidence: ART initiation§ — <3 months from diagnosis: 43 (24.7); ≥3 months from diagnosis: 131 (75.3); §Data available for 174/186 individuals. 

Rationale: The paper reports only timing of ART initiation, not which drug classes or regimens were received.

Answer: NA
"""

"""
Question: 4302 

Evidence: ART initiation§ data were summarized without regimen details. Pol sequencing targeted protease and RT; integrase was not sequenced or discussed.

Rationale: There is no information on integrase inhibitor use among participants.

Answer: No
"""

"""
Question: 4303 

Evidence: ART initiation§ — timing data presented; no regimen or drug class details provided. Transmitted drug resistance by PI class is listed, but not treatment received.

Rationale: The paper does not report actual receipt of protease inhibitors by individuals.

Answer: No
"""

"""
Question: 4304 

Evidence: ART initiation§ — timing data presented; no regimen details. 

Rationale: The paper does not state what ART regimens were used, so it cannot be determined whether all received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: We studied 186 treatment-naïve participants with primary HIV-1 Infection (PHI). 

Rationale: Being treatment-naïve implies no prior exposure to any ART classes, including INSTIs, at the time of sequencing.

Answer: Yes
"""

"""
Question: 4403 

Evidence: ART initiation§ — timing data presented; no regimen details. 

Rationale: The number of individuals receiving more than one regimen is not reported.

Answer: NA
"""

"""
Question: 4404 

Evidence: ART initiation§ — timing data presented; no regimen details. 

Rationale: The number receiving more than two regimens is not reported.

Answer: NA
"""

"""
Question: 4405 

Evidence: ART initiation§ — timing data presented; no regimen details. 

Rationale: Without regimen data, it cannot be determined whether all received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: ART initiation§ — timing data presented; no regimen details. 

Rationale: The paper does not report whether each individual received exactly one regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: ART initiation§ — timing data presented; no regimen or specific drug details. 

Rationale: The paper does not report which drugs (e.g., dolutegravir) were used.

Answer: NA
"""

"""
Question: 4502 

Evidence: ART initiation§ — timing data presented; no regimen or specific drug details. 

Rationale: The paper does not report darunavir use.

Answer: NA
"""

"""
Question: 5101 

Evidence: TDR was present in 16/186 (8.6%) participants. Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list...

Rationale: The number with one or more transmitted resistance mutation is 16.

Answer: 16
"""

"""
Question: 5102 

Evidence: Pol sequences (containing the full-length protease and the first 330–335 reverse transcriptase (RT) codons)... Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with additional RT mutations...

Rationale: Integrase was not sequenced or analyzed; INSTI resistance mutations were not assessed or reported.

Answer: NA
"""

"""
Question: 5103 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list, with the additional RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I. TDR was present in 16/186 (8.6%) participants.

Rationale: Although NRTI mutations (some relevant to TDF) were within the evaluation list, the paper does not provide counts for TDF-specific resistance; thus, the number cannot be determined.

Answer: NA
"""

"""
Question: 5104 

Evidence: Pol sequences (protease and RT) were analyzed; integrase was not sequenced. Transmitted drug resistance was evaluated per WHO 2009 list with additional RT mutations.

Rationale: The study did not evaluate or report INSTI-resistance mutations; therefore none are reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... Transmission clusters were identified by phylogenetic analysis...

Rationale: The paper reports only genotypic analyses; no phenotypic susceptibility testing method is described.

Answer: NA
"""

"""
Question: 6102 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... 

Rationale: No IC50/IC90 values are reported.

Answer: No
"""

"""
Question: 6103 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... 

Rationale: No fold-change IC50 values are reported.

Answer: No
"""

"""
Question: 6104 

Evidence: Transmitted drug resistance (TDR) was evaluated according to the WHO 2009 list... 

Rationale: No phenotypic susceptibility assay is described.

Answer: NA
"""

"""
Question: 6105 

Evidence: The methods and results focus on genotyping, subtyping, and clustering; no assays of replication capacity are described.

Rationale: There is no mention of replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: The paper does not describe any phenotypic susceptibility testing or drugs tested phenotypically. 

Rationale: Only genotypic resistance assessment is presented.

Answer: NA
"""

"""
Question: 7101 

Evidence: Pol sequences were obtained by Sanger sequencing. All HIV-1 pol genotype analyses were performed on plasma samples.

Rationale: The sequences are from clinical samples; there is no indication of site-directed mutagenesis.

Answer: No
"""

"""
Question: 7102 

Evidence: Pol sequences were obtained by Sanger sequencing. Transmission clusters were identified by phylogenetic analysis...

Rationale: The study did not perform in vitro passage; all sequences derive from patient plasma.

Answer: No
"""